Advances in Pseudoprogression of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
The advent of immune checkpoint inhibitors (ICIs) has greatly improved the prognosis of advanced lung cancer patients, but can lead to pseudoprogression (PsP), which complicates clinical evaluation and management. PsP is manifested as temporary enlargement of the tumour or the appearance of new lesi...
Furkejuvvon:
| Váldodahkkit: | , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Chinês |
| Almmustuhtton: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2024-04-01
|
| Ráidu: | Chinese Journal of Lung Cancer |
| Fáttát: | |
| Liŋkkat: | http://dx.doi.org/10.3779/j.issn.1009-3419.2024.101.10 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|